These studies also lay the foundation for an area of research on the immunosuppressive effects of neurons in the GBM TME and demonstrate that therapeutic inhibition of CaMKK2 may prolong survival in patients with GBM, as well as improve the effectiveness of ICB in this setting. This evidence concerns the gene CAMKK2 and glioblastoma.